Valbiotis is presenting new preclinical evidence for TOTUM•448 against liver metabolic diseases at the Annual Congress of the European Association for the Study of the Liver (EASL) in Vienna, Austria from 21 to 24 June. After AASLD in the United States in 2022, the selection of these new results by the main European congress of hepatology confirms the value of the TOTUM•448 program against liver metabolic diseases (NAFL and NASH). The work presented demonstrates a broad benefit on the main markers of the progression of these diseases: reduction of fat accumulation in the liver (steatosis), reduction of ballooning and improvement of certain molecular markers of inflammation and fibrosis.
See poster